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Background: Comorbidities are frequent in subjects with COPD, but their contribution to
health-related quality of life (HRQoL) impairment is not clearly established.
Methods: Cross-sectional analysis of data from the French COPD cohort Initiatives BPCO. Data
were recorded in stable state and included spirometry, dyspnea (modified Medical Research
Council e mMRC-scale), mood disorders (hospital anxietyedepression scale) and physician-COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; HAD, hospital
, hospital anxiety and depression scale-anxiety; HAD-D, hospital anxiety and depression scale-
lity of life; IQR, interquartile range; mMRC, modified Medical Research Council dyspnea scale; SGRQ,
e.
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Depressiondiagnosed comorbidities including diabetes, hypertension, coronary artery disease, chronic
heart failure, venous thromboembolism. HRQoL was assessed using the disease-specific St.
George’s Respiratory Questionnaire (SGRQ). Stepwise forward and backward multiple regres-
sion analyses were performed to examine the contribution of comorbidities to SGRQ scores.
Results: Data are median [IQR]. 326 COPD subjects were analyzed: male 77%, age 65.0 [57.0;
72.0] years, FEV1 48.9 [34.7; 65.9]% predicted. SGRQ total score was 44.2 [30.0; 61.2]. In
univariate analysis, positive correlations were found between SGRQ total scores and dyspnea
and exacerbations/patient/year, whereas negative correlations were found with FEV1. SGRQ
total scores were increased in women (P Z 0.06), and in subjects with low BMI, anxiety or
depression (each analysis, P < 0.001), but not in subjects with cardiovascular comorbidities
or diabetes. In multivariate analyses, major independent determinants of SGRQ total score
included dyspnea, exacerbations/patient/year and depression. Low BMI, coronary artery
disease and FEV1 were also independently associated with SGRQ total score, but their contri-
bution was only modest.
Conclusions: These data suggest that in the presence of dyspnea and exacerbation, depression
is the most important contributor to HRQoL impairment measured by SGRQ in COPD subjects,
whereas other comorbidities and FEV1 have only limited impact.
ª 2012 Elsevier Ltd. All rights reserved.Background
Chronic obstructive pulmonary disease (COPD) is a leading
cause of mortality and morbidity worldwide.1 It is charac-
terized by progressive airflow limitation, and COPD severity
is assessed using forced expiratory volume in 1 s (FEV1).
2
However FEV1 is poorly correlated with clinical manifesta-
tions of the disease3 and standardized measurement of
patient-related outcomes (e.g., health status) has been
proposed for more comprehensive assessment of disease
severity.4
Health-related quality of life (HRQoL) measurement
using validated questionnaires provides a standardized
method for assessing the impact of disease on patients’
daily lives, activity and well-being.4 Generic questionnaires
are designed to assess health status irrespective of under-
lying disease, while disease-specific questionnaires tend to
be more sensitive to change. The disease-specific St.
George’s Respiratory Questionnaire (SGRQ)5 is the most
frequently used questionnaire for assessing HRQoL in COPD
subjects. Large epidemiological studies have used SGRQ
and have demonstrated that HRQoL was impaired in COPD
subjects,6 and was independently associated with hospital
readmission7 and mortality.8
Comorbidities, defined as other chronic diseases asso-
ciated with COPD (irrespective of the nature-causal or not-
of their link with the disease), are frequently present in
COPD patients and their impact is increasingly recognized.9
High rates of cardiovascular diseases, diabetes, and mood
disorders (e.g., anxiety and depression) were reported in
COPD patients.9,10 These comorbidities were reported to
increase the risk of mortality and hospitalizations in COPD
patients,11,12 and they exponentially increased the costs of
treatment.13
Determinants of HRQoL impairment in COPD patients, as
measured by the SGRQ, have been the subject of several
studies. Respiratory features, including the severity of
airflow limitation,14 dyspnea15 and repeated exacerba-
tions16 were reported to be independently associated withimpaired HRQoL. Recent studies have further suggested
that COPD subjects with anxiety and/or depression had
impaired HRQoL,12,17,18 but only scarce data exist on the
impact of other comorbidities (e.g., cardiovascular diseases
and diabetes) on HRQoL. In previous studies, subjects with
severe comorbidities were either excluded,19 not re-
ported20 or examined using the rather imprecise Charlson
index.21,22 In a pioneer study published in 1997, Ferrer
et al. found that comorbid conditions partly influenced
SGRQ scores23: the relationship was clear in mild COPD
cases but absent in those with severe airflow obstruction.
However, comorbidities were reported by organ involve-
ment (e.g., “heart problems”) and the relative contribution
of individual comorbidities was not reported. Therefore,
the contribution of comorbidities to the HRQoL impairment
found in COPD patients has not been clearly established.
In the present study, the relation between physician-
diagnosed comorbidities and SGRQ scores was analyzed in
patients included in the INITIATIVES BPCO cohort.24 The
main goal of these analyses was to evaluate the indepen-
dent contribution of comorbidities e including mood
disorders, metabolic and cardiovascular comorbidities e to
SGRQ scores, in the presence of known respiratory factors
associated with HRQoL impairment such as dyspnea and
exacerbation frequency.Methods
The INITIATIVES BPCO cohort
COPD subjects included in the present analysis were
recruited in the INITIATIVES BPCO cohort between January
2005 and August 2009. INITIATIVES BPCO cohort is a real-
world cohort of spirometry-diagnosed COPD patients iden-
tified in university hospitals located throughout France.
Data are recorded in a standardized case report form but,
due to the real-world nature of patient’s care, datasets do
not have to be complete to include a patient. Only
Comorbidities and HRQoL in COPD 235demographic characteristics and spirometry are manda-
tory. Detailed information about this cohort can be found in
a previous report.24 Respiratory physicians prospectively
recruited subjects in stable condition (no history of exac-
erbation requiring medical treatment during the previous 4
weeks) with a diagnosis of COPD based on a post-
bronchodilator FEV1/FVC ratio <70%.
2 The study was
approved by the Ethics Committee of Versailles (France)
and all subjects provided written informed consent.
Data collection
The standardized characterization process covered demo-
graphic data, cumulative tobacco smoking, and COPD
characteristics (including symptoms and spirometry) in
stable condition. Pulmonary function tests were performed
according to international standards.25 Severity of airflow
obstruction was evaluated according to GOLD classifica-
tion.2 The number of self-reported acute exacerbations of
COPD during the previous year was determined. Physician-
diagnosed cardiovascular comorbidities (including conges-
tive heart failure, coronary artery disease, and hyperten-
sion) were identified from the patient files. Diabetes
mellitus was considered present when patients were
treated with insulin or oral antidiabetic drugs. Malnutrition
was defined as a body mass index (BMI) 18.5 kg/m2 and
obesity as a BMI >30 kg/m2.26 Dyspnea was assessed using
the modified MRC scale.27 The hospital anxiety and
depression (HAD) scale was used to examine mood disor-
ders. This 14-item self-questionnaire has two 7-item
subscales for anxiety (HAD-A) and depression (HAD-D). A
score of 10 or higher on either subscale is closely associated
with the presence of the corresponding mood disorder.12
Health-related quality of life was evaluated using the
SGRQ.5
For the purpose of these analyses only subjects with
complete data for comorbidities (coronary artery disease,
chronic heart failure, diabetes, hypertension), mMRC,Table 1 Characteristics of COPD subjects recorded in stable st
Study population
(complete data) n Z 32
Male, n (%) 250 (77)
Age, yr 65.0 [57.0; 72.0]
Smoking, pack-yr 41.6 [28.0; 57.3]
FEV1% predicted 48.8 [34.7; 65.9]
SGRQ, total score 44.0 [29.9; 60.2]
Body mass index (kg/m2) 24.6 [20.8; 28.0]
Dyspnea, MMRC scale 2.0 [1.0; 3.0]
Exacerbation/patient/yr 1.0 [0.0; 3.0]
Comorbidities, n (%)
Coronary artery disease 49 (15)
Chronic heart failure 50 (15)
Hypertension 113 (35)
Diabetes mellitus 37 (11)
Venous thromboembolism 24 (7)
All data are median [IQR] or n (%). SGRQ: St. George’s Respiratory Que
Medical Research Council scale; HAD: Hospital Anxiety Depression Sca
a Missing in 174 patients.hospital anxiety and depression (HAD) scale and SGRQ score
were selected.
Statistical analysis
Data are presented as median [interquartile range; IQR] or
n (%). Univariate associations between SGRQ scores and
other variables were analyzed using Kendall tau b correla-
tions and Wilcoxon’s test for continuous and categorical
variables, respectively. Stepwise forward and backward
multiple regression analyses were performed to examine
determinants of SGRQ total score. In these analyses,
comorbidities were included as individual variables. Exac-
erbations were included either as a whole or as severe
exacerbations only (i.e., exacerbations requiring hospital-
ization). Because we found that low BMI, but not obesity,
was associated with increased SGRQ total score in the
univariate analysis, we analyzed BMI as a categorical vari-
able (low vs. normal þ increased BMI). Similarly, determi-
nants of SGRQ activity, symptom and impact scores were
determined using stepwise forward and backward multiple
regression analyses. All covariates with a P-value <0.15
were entered into the multivariate regression models, and
successively excluded if they were not associated with the
outcome (P < 0.10). Analyses were performed using the
SAS 9.2 statistical software.
Results
Patients
The INITIATIVES BPCO cohort contained data on 633 COPD
subjects. Data on SGRQ scores were missing in 174 subjects
and evaluation of mood disorders by the HAD scale was
missing in 210 subjects. Comparison of the 326 (51.5%)
subjects with complete data (see Methods) to the 307
(48.5%) subjects with incomplete data is shown in Table 1.ate.
6
Excluded subjects
(incomplete data) n Z 307
P value
253 (82) 0.07
65.0 [57.0; 73.0] 0.56
40.0 [24.0; 57.0] 0.25
48.9 [35.6; 65.4] 0.83
42.3 [30.3; 59.1]a 0.29
24.8 [21.8; 28.2] 0.30
2.0 [1.0; 2.0] 0.34
1.0 [0.0; 2.0] 0.12
49 (16) 0.74
33 (11) 0.08
113 (37) 0.57
41 (13) 0.44
19 (6) 0.56
stionnaire; FEV1: forced expiratory volume in 1 s; MMRC: Modified
le.
236 P.-R. Burgel et al.Subjects with complete data had a trend toward higher
rates of chronic heart failure (15% vs. 11%, P Z 0.08), and
toward a higher proportion of women (23 vs. 18%,
P Z 0.07). No other differences were found between
included and excluded subjects.
Among the 326 subjects included in the analyses, all
GOLD stages were represented with 21 (6.4%) patients in
GOLD I, 135 (41.4%) patients in GOLD II, 110 patients
(33.7%) in GOLD III and 60 patients (18.5%) in GOLD IV. Low
BMI (18.5 kg/m2) was found in 36 subjects (11%) and
obesity (BMI >30 kg/m2) in 52 subjects (16%). Previously
diagnosed comorbidities were highly prevalent (see Table
1): only 115 patients (35%) had no comorbidities, whereas
171 patients (53%) had 1 or 2 comorbidities and 40 patients
(12%) had 3 or more comorbidities. At least one cardio-
vascular comorbidity (defined as hypertension, coronary
artery disease, or chronic heart failure) was present in 158
patients (48%). No significant difference was found among
GOLD stages for cardiovascular comorbidities, anxiety or
depression (not shown).
Univariate determinants of SGRQ scores
Median [IQR] SGRQ total score was 44.0 [29.9; 60.2] and
increased with GOLD stages: GOLD I 24.5 [16.3; 46.0], GOLD
II 35.8 [25.0; 51.9], GOLD III 49.3 [34.5; 60.2] and GOLD IV
63.3 [45.6; 70.9] (P < 0.0001 for trend, using Kendall tau b).
Correlation of SGRQ total score with FEV1% pred and GOLD
stages is presented in Fig. 1. SGRQ total scores also
increased with exacerbation frequency and more severe
dyspnea (see Table 2). Median [IQR] SGRQ total scores were
40 [27e58] in subjects without hospitalization for exacer-
bation in the previous year (n Z 243), 46 [35e62] in
subjects who had one hospitalization (n Z 50) and 63Table 2 Univariate correlations of continuous variables
with SGRQ scores. Bold represents statistical significance.
Variables SGRQ
scores
Coefficients of
correlation
P values
Age Total 0.02 0.68
Activity 0.03 0.39
Impact 0.03 0.43
Symptom 0.06 0.14
Pack-yr Total 0.03 0.31
Activity 0.06 0.15
Impact 0.02 0.63
Symptom 0.04 0.26
FEV1% Total 0.29 <0.001
Activity 0.27 <0.001
Impact 0.28 <0.001
Symptom 0.16 <0.001
Exacerbations/
patient/yr
Total 0.31 <0.001
Activity 0.22 <0.001
Impact 0.29 <0.001
Symptom 0.37 <0.001
Dyspnea (mMRC) Total 0.53 <0.01
Activity 0.58 <0.001
Impact 0.47 <0.001
Symptom 0.21 <0.001[51e71] in subjects with 2 hospitalizations (n Z 33; all
comparisons, P < 0.001). The relationship between
comorbidities and SGRQ total scores is summarized in Fig. 2
and Table 3. Subjects with low BMI (18.5 kg/m2), anxiety,
or depression had higher SGRQ total scores, whereas those
with coronary artery disease, chronic heart failure and
previous venous thromboembolism had no significant
difference in SGRQ total scores. No significant increase in
SGRQ total score was found in subjects with cardiovascular
comorbidities or with multiple comorbidities (see Fig. 2).
Univariate determinants of SGRQ activity, impact and
symptom scores are described in Tables 2 and 3.
Multivariate determinants of SGRQ scores
Results of the stepwise multiple regressions for SGRQ total
score and for SGRQ activity, impact and symptom scores are
shown in Table 4. Major (as indicated by high R2 values)
determinants of SGRQ total score included dyspnea and
exacerbations/patient/year (but not hospitalizations/
patient/yr). In the presence of these variables, the most
important contributor to SGRQ total score was depression.
Low BMI, coronary artery disease and FEV1 (% predicted)
were also independently associated with impaired HRQoL,
but their contribution was modest (as shown by low R2
values). Fig. 3 summarizes the factors independently
associated with SGRQ total, symptoms, activity and impact
scores.
Discussion
The present study confirmed that dyspnea and exacerba-
tions, but not airflow limitation, are major determinants of
SGRQ total score in a real-life cohort of stable COPD
patients. In the presence of these variables, depression was
the most important variable associated with SGRQ total
score. Although low BMI and coronary artery disease also
affected HRQoL, their impact was only modest. Other
cardiovascular comorbidities, obesity and diabetes had no
significant impact.
The weak negative correlation between FEV1% predicted
and SGRQ total score confirmed that HRQoL is worsening
with increasing spirometric severity.14,28 However, SGRQ
total scores were highly variable within each GOLD stage,
confirming recently published data.3 Multivariate analysis
revealed that the most important determinants of SGRQ
total scores were dyspnea and exacerbations. Although
subjects with repeated hospitalizations had worse HRQoL,
repeated hospitalizations were not retained in our multi-
variate model, presumably because (i) subjects with
repeated hospitalizations also experienced multiple non-
hospitalized exacerbations, and (ii) non-hospitalized exac-
erbations were more numerous than those requiring
hospitalization. These findings are consistent with previous
reports showing that the severity of dyspnea is more closely
associated with SGRQ total score than the level of FEV1
impairment15,27 and that higher exacerbation frequency is
associated with worse HRQoL independently of the level of
dyspnea.16
The major focus of this study was the contribution of
comorbidities to HRQoL impairment, as examined using the
Figure 1 Correlation between SGRQ total scores and FEV1 in 326 COPD patients. Numbers on the graph indicate GOLD stage. Each
number corresponds to results obtained in an individual subject.
Comorbidities and HRQoL in COPD 237SGRQ. Our univariate data indicated that COPD subjects
with anxiety or depression had worse HRQoL, confirming
previous reports.17,22,29 However, in the presence of dysp-
nea and exacerbations, only depression (but not anxiety)
significantly contributed to HRQoL. Balcells et al. reported
that anxiety and/or depression impaired HRQoL measured
by SGRQ in stable COPD patients,22 but the analysis was notFigure 2 SGRQ total scores by comorbidities, cardiovascular com
SGRQ total scores by comorbidities (absent, open bars; or present
that display minimum and maximum values, and 25th, 50th and 75th
chronic heart failure, VTE: venous thromboembolism. BMI: body m
obesity >30 kg/m2), CV comorbidities: cardiovascular comorbidities
heart failure or hypertension); all comorbidities: numbers of como
diabetes, venous thromboembolism.controlled for exacerbations. Ng et al. reported that
depression, but not anxiety, was associated with decreased
HRQoL, when adjusting the analyses for dyspnea and
hospitalizations.12 The latter results were obtained when
including subjects with suspected anxiety and/or depres-
sion (HAD subscale values 8), and our study extend and
reinforce these data by showing that comparable resultsorbidities and total numbers of comorbidities. Comparison of
, gray bars). Each box plot is composed of five horizontal lines
percentiles of the variable. CAD: coronary artery disease, CHF:
ass index (comorbidities include malnutrition 18.5 kg/m2 and
(defined as the patient having coronary artery disease, chronic
rbidities among cardiovascular comorbidities, low BMI, obesity,
Table 3 Relationship of categorical variables with SGRQ scores. Bold represents statistical significance.
Variables SGRQ scores Variable present Variable absent P values
Male sex Total 42.4 [27.6; 60.2] 49.3 [36.7; 61.5] 0.06
Activity 59.4 [36.1; 73.7] 66.2 [53.6; 80.5] 0.02
Impact 28.1 [15.0; 50.3] 36.7 [22.8; 53.5] 0.06
Symptom 56.3 [41.0; 66.8] 55.4 [37.2; 68.7] 0.92
Current smokers Total 44.3 [29.9e62.1] 43.5 [29.6e59.1] 0.71
Activity 59.5 [41.4; 72.9] 60.3 [41.5; 79.2] 0.46
Impact 32.1 [15.9; 48.4] 31.7 [18.1; 50.7] 0.95
Symptom 61.0 [48.0; 79.3] 53.5 [37.6; 63.9] <0.001
Chronic bronchitis Total 44.4 [30.0e60.6] 42.4 [27.6e59.8] 0.49
Activity 59.9 [41.5; 79.1] 60.2 [42.4; 79.1] 0.80
Impact 32.6 [17.8; 50.5] 29.6 [15.0; 50.2] 0.98
Symptom 57.5 [43.7; 70.0] 42.5 [31.1; 56.2] <0.001
Chronic heart failure Total 43.0 [33.5e64.1] 44.2 [28.5e59.8] 0.33
Activity 63.8 [53.5; 81.3] 59.5 [41.4; 76.3] 0.13
Impact 34.8 [20.5; 54.3] 31.7 [16.0; 50.2] 0.44
Symptom 55.7 [44.6; 65.4] 56.3 [39.3; 67.5] 0.93
Coronary artery disease Total 47.1 [33.5e62.2] 43.6 [29.6e59.8] 0.34
Activity 60.5 [47.5; 73.9] 59.9 [41.4; 79.1] 0.58
Impact 35.0 [19.6; 54.4] 31.6 [16.1; 48.9] 0.31
Symptom 57.3 [43.2; 69.8] 55.7 [40.8; 66.8] 0.42
Diabetes mellitus Total 42.4 [30.0e60.6] 44.1 [29.9e60.0] 0.85
Activity 66.2 [47.7; 81.3] 59.5 [41.4; 79.0] 0.28
Impact 27.7 [18.9; 50.5] 32.3 [17.0; 50.3] 0.87
Symptom 52.8 [34.3; 70.1] 56.3 [41.0; 67.0] 0.61
Hypertension Total 40.3 [25.0e57.8] 46.4 [32.8e62.1] 0.03
Activity 59.4 [35.5; 73.0] 60.3 [47.5; 79.7] 0.13
Impact 27.7 [14.9; 47.8] 34.6 [19.3; 51.2] 0.06
Symptom 47.6 [34.0; 60.2] 57.6 [44.7; 69.8] <0.001
Venous thromboembolism Total 53.8 [35.7e71.6] 43.3 [29.6e59.8] 0.09
Activity 72.9 [59.8; 86.3] 59.5 [41.4; 73.7] 0.03
Impact 40.4 [22.3; 61.0] 30.9 [16.3; 50.2] 0.16
Symptom 61.0 [41.8; 68.7] 55.7 [41; 66.8] 0.46
Anxiety (HAD-A  10) Total 55.9 [34.8e68.1] 41.2 [27.3e55.5] <0.001
Activity 66.3 [47.2; 85.9] 59.5 [41.0; 73.0] <0.001
Impact 43.8 [25.1; 60.4] 26.9 [14.7; 43.7] <0.001
Symptom 60.9 [49.7; 76.3] 53.5 [36.7; 63.1] <0.001
Depression (HAD-D  10) Total 59.2 [43.8e70.7] 40.5 [27.2e57.1] <0.001
Activity 79.1 [59.4; 92.5] 59.5 [35.5; 73.0] <0.001
Impact 46.5 [32.0; 66.2] 27.0 [14.8; 46.4] <0.001
Symptom 63.0 [43.7; 80.5] 54.9 [38.4; 64.2] 0.003
238 P.-R. Burgel et al.are obtained when the analyses are limited to subjects in
whom depression was highly probable (HAD subscale values
10).
The presence of cardiovascular comorbidities or dia-
betes was not associated with significantly higher SGRQ
total scores in univariate analysis: although coronary artery
disease was found to contribute independently to HRQoL in
multivariate analysis integrating respiratory determinant of
SGRQ total scores, its contribution was only modest.
Further, patients with multiple comorbidities had no
significant increase in SGRQ total score. These results are in
contradiction with those obtained by Balcells et al., who
found that the presence of comorbidities, as assessed using
the Charlson index, was associated with increased SGRQ
scores in a cohort of stable COPD subjects.22 de Torres
et al. also reported that the Charlson index wasindependently associated with SGRQ total score in male,
but not in female, with COPD.21 The Charlson index is an
imprecise descriptor of comorbidities in COPD subjects,
limiting the comparability of these data to what is reported
here. Further, these studies did not include data on exac-
erbations,21,22 a major determinant of SGRQ. In a recent
report that studied a large number of subjects (n Z 1817
subjects) in primary care across Europe, the authors re-
ported that patients with 3 comorbidities had a signifi-
cantly worse SGRQ total score vs. patients with 1e2
comorbidities or no comorbid condition.6 In the latter
study, subjects with cardiovascular comorbidities had only
a small increase in SGRQ total scores vs. subjects with no
cardiovascular comorbidities. The difference was statisti-
cally significant, but was less than the minimal clinically
important difference (MCID).6 The present results confirm
Table 4 Variables associated with SGRQ scores in step-
wise multiple regressions.
Variables P values Cumulative R2
SGRQ total score
Dyspnea (mMRC) <0.0001 0.43
Exacerbations/patient/yr <0.0001 0.50
Depression 0.0001 0.52
Low BMI (18.5 kg/m2) 0.002 0.53
Coronary artery disease 0.02 0.54
FEV1% predicted 0.02 0.55
0.55
SGRQ activity score
Dyspnea (mMRC) <0.0001 0.47
Depression 0.0006 0.49
FEV1% predicted 0.004 0.50
Exacerbations/patient/yr 0.02 0.51
Coronary artery disease 0.04 0.52
Low BMI (18.5 kg/m2) 0.07 0.52
Anxiety 0.07 0.53
0.53
SGRQ impact score
Dyspnea (mMRC) <0.0001 0.34
Exacerbations/patient/yr <0.0001 0.41
Depression 0.0001 0.43
Low BMI (18.5 kg/m2) 0.006 0.44
Coronary artery disease 0.04 0.45
FEV1% predicted 0.04 0.46
0.46
SGRQ symptom score
Exacerbations/patient/yr <0.0001 0.22
Chronic bronchitis <0.0001 0.27
Dyspnea (mMRC) <0.0001 0.31
Hypertension 0.0007 0.33
Anxiety 0.007 0.35
0.35
Figure 3 Schematic representation of independent deter-
minants of SGRQ activity, impact and symptom scores. Each
score is represented by a circle surrounding the variables that
were independently associated with this score in multiple
stepwise regression analysis. Variables in bold were indepen-
dent determinants of SGRQ total score. Variables outside of the
circles were not associated with SGRQ scores.
Comorbidities and HRQoL in COPD 239that cardiovascular comorbidities are not associated with
clinically-significant increase in SGRQ scores, and extend
these findings by showing that diabetes and obesity are not
independently associated with SGRQ scores.
The present study has several strengths. Data on
comorbidities were prospectively recorded and were based
on physician-diagnosed comorbidities for cardiovascular
comorbidities and diabetes, and systematic assessment of
anxiety and depression using a validated questionnaire
(HAD scale). The cut-off values (10) for each HAD subscale
were chosen to select subjects in whom the diagnosis of
anxiety and/or depression was highly probable.30 Some
limitations also have to be recognized. Our patients were
recruited in pulmonary clinics of university hospitals and
therefore may not represent the COPD population at large.
However, these patients had a wide range of airflow limi-
tation and our subjects in GOLD stage 2, 3, and 4 had
median [IQR] values of SGRQ total scores that were
remarkably comparable with those found by Jones et al. in
a large sample of COPD patients recruited in primary care
across Europe.6 HRQoL was measured using SGRQ, but no
generic HRQoL questionnaire was utilized. In a recent
study, the authors suggested that SGRQ cannot capture allaspects of health status in COPD patients,31 and the use of
a generic questionnaire may have resulted in different
results. However, when designing the cohort in the early
2000’ it was pragmatically decided to limit recorded HRQoL
evaluation to the SGRQ, which is often the only question-
naire used in cohort studies and clinical trials. Further
studies using multiple questionnaires, including generic
HRQoL questionnaires and newly developed short COPD-
specific questionnaires (e.g., CAT,32 VSRQ33 and CCQ34),
should be planned to fully understand the impact of
comorbidities in this context. Some frequent comorbidities
(e.g., osteoporosis, anemia, lung cancer, renal failure and
atrial fibrillation) were not assessed in this study; thus, we
were unable to determine their impact on SGRQ score.
Because our database was not designed to match individual
comorbidities with their treatments, we were unable to
evaluate whether subjects were receiving appropriate
treatments for comorbidities. In addition, it must be out-
lined that many comorbidities (e.g., left heart failure,35
osteoporosis36) often remain underdiagnosed; the possible
impact of such undiagnosed comorbidities on HRQoL will
require further studies.
Improvement of health status is one of the major goals
of the treatment in COPD subjects.2 Our study confirms that
dyspnea and exacerbations are important targets for
improving HRQoL in COPD subjects. These results are
consistent with data showing that pharmacologic inter-
ventions that improve dyspnea and reduce exacerbations
(e.g., long-acting bronchodilators alone or in combination
with inhaled corticosteroids37,38) also improve HRQoL.
Pulmonary rehabilitation, which improves dyspnea,
decreases exacerbations and depression39 and is associated
with weight gain when combined with integrated nutri-
tional program,40 also improves HRQoL. Our results also
240 P.-R. Burgel et al.reinforce the hypothesis that treatment of depression may
result in improvement of HRQoL in COPD subjects.10 They
concur with recent data from von Leupoldt et al. who re-
ported that, in COPD patients undergoing pulmonary reha-
bilitation, depression and anxiety are associated with
poorer HRQoL and increased symptoms, both at baseline
and over the course of rehabilitation. These findings led the
authors to suggest that their early diagnosis and treatment
may provide clinical benefits in these patients.41 Because
the present data was obtained in a cross-sectional design
we could not exclude reverse causation between poor
HRQoL and mental comorbidities, confirmation for this
concept will require appropriate clinical trials.
Conclusions
In conclusion, we found that in the presence of dyspnea and
exacerbations, depression is the most important contrib-
utor to HRQoL impairment measured by SGRQ in COPD
subjects, whereas other comorbidities and FEV1 have only
limited impact. These data suggest that, although the SGRQ
is of great value for evaluating the impact of COPD on
HRQoL, additional instruments should be employed to
measure the impact of co-existing non-communicable
chronic diseases in patients with COPD.
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